India, Sept. 2 -- Owkin, an AI-driven company focused on transforming drug discovery and development, announced a license agreement with Boehringer Ingelheim for its K Pro AI Scientist platform, along with multimodal oncology and immunology patient data. The collaboration aims to accelerate discovery across multiple therapeutic areas by combining advanced AI reasoning with deep biological datasets.
The agreement builds on a 2025 pilot project in which Owkin provided Boehringer with spatial insights into the tumor microenvironment of a gene target using its MOSAIC dataset. Under the new deal, Owkin will license multimodal oncology data and generate additional immunology datasets through its global patient data network.
Boehringer's teams w...